Keybanc analyst Justin Patterson initiates coverage on Bumble (NASDAQ:BMBL) with a Sector Weight rating.
AcelRx Pharmaceuticals Q2 EPS $(0.06) Beats $(0.07) Estimate, Sales $570.00K Beat $550.00K Estimate
AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 25 percent increase over losses of $(0.08) per share
